QSAR Differential Model for Prediction of SIRT1 Modulation using Monte Carlo Method

Abstract

Silent information regulator 2 homologue one (SIRT1) modulators have therapeutic potential for a number of diseases like cardiovascular, metabolic, inflammatory and age related disorders. Here, we have studied both activators and inhibitors of SIRT1 and constructed differential quantitative structure activity relationship (QSAR) models using CORAL software by Monte Carlo optimization method and SMILES notation. 3 splits divided into 3 subsets: sub-training, calibration and test sets, were examined and validated with a prediction set. All the described models were statistically significant models. The values of sensitivity, specificity, accuracy and Matthews’ correlation coefficient for the validation set of best model were 1.0000, 0.8889, 0.9524 and 0.9058, respectively. In mechanistic interpretation, structural features important for SIRT1 activation and inhibition have been defined.

• References

• 1 Ekwall K. Genome-wide analysis of HDAC function. Trends Genet 2005; 21: 608-615
• 2 Kumar A, Chauhan S. How much successful are the medicinal chemists in modulation of SIRT1: A critical review. Eur J Med Chem 2016; 119: 45-69
• 3 Benigni R. Alternatives to the carcinogenicity bioassay for toxicity prediction: are we there yet?. Expert Opin Drug Met 2012; 8: 407-417
• 4 Mor S, Nagoria S, Kumar A et al. QSAR studies and design of some tetracyclic 1,4-benzothiazines as antimicrobial agents. Drug Res (Stuttg) 2016; 66: 436-443
• 5 Bansal A, Kumar P, Narasimhan B. Synthesis, antimicrobial evaluation and QSAR studies of 2-hydroxy propanoic acid derivatives. Drug Res (Stuttg) 2014; 64: 240-245
• 6 Fernández A, Lombardo A, Rallo R et al. Quantitative consensus of bioaccumulation models for integrated testing strategies. Expert Opin Drug Metab Toxicol 2012; 45: 51-58
• 7 CORAL . http://www.insilico.eu/coral/ Accessed on May 9, 2016
• 8 Toropov AA, Toropova AP. CORAL software: prediction of carcinogenicity of drugs by means of the Monte Carlo method. Eur J Pharm Sci 2014; 52: 21-25
• 9 Worachartcheewan A, Nantasenamat C, Isarankura-Na-Ayudhya C et al. QSAR study of H1N1 neuraminidase inhibitors from influenza A virus. Lett Drug Des Discov 2014; 11: 420-427
• 10 Martinez JCG, Duchowicz PR, Estrada MR et al. QSAR study and molecular design of open-chain enaminones as anticonvulsant agents. Int J Mol Sci 2011; 12: 9354-9368
• 11 Masand VH, Toropov AA, Toropova AP et al. QSAR models for antimalarial activity of 4-aminoquinolines. Curr Comput Aided Drug Des 2014; 10: 75-82
• 12 Toropova AP, Toropov AA, Veselinovic JB et al. QSAR models for HEPT derivates as NNRTI inhibitors based on Monte Carlo method. Eur J Med Chem 2014; 77: 298-305
• 13 Toropov AA, Toropova AP, Benfenati E et al. QSAR models for inhibitors of physiological impact of Escherichia coli that leads to diarrhea. Biochem Biophys Res Commun 2013; 432: 214-225
• 14 Mullen LMA, Duchowicz PR, Castro EA. QSAR treatment on a new class of triphenylmethyl-containing compounds as potent anticancer agents. Chemometr Intell Lab Syst 2011; 107: 269-275
• 15 Worachartcheewan A, Mandi P, Prachayasittikul V et al. Large-scale QSAR study of aromatase inhibitors using SMILES-based descriptors. Chemometr Intell Lab Syst 2014; 138: 120-126
• 16 García J, Duchowicz PR, Rozas MF et al. A comparative QSAR on 1,2,5-thiadiazolidin-3-one 1,1-dioxide compounds as selective inhibitors of human serine proteinases. J Mol Graph Model 2011; 31: 10-19
• 17 Bemis JE, Vu CB, Xie R et al. Discovery of oxazolo[4,5-b]pyridines and related heterocyclic analogs as novel SIRT1 activators. Bioorg Med Chem Lett 2009; 19: 2350-2353
• 18 Vu CB, Bemis JE, Disch JS et al. Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators. J Med Chem 2009; 52: 1275-1283
• 19 Cohen HY, Miller C, Bitterman KJ et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004; 305: 390-392
• 20 Bemis JE, Disch JS, Ng PY et al. Sirtuin modulating compounds. US Patent 2011; 7,893,086
• 21 Oalmann C, Perni RB, Disch JS et al. Patent Appl; PCT WO 2009/00058348
• 22 Yang H, Zhang W, Pan H et al. SIRT1 activators suppress inflammatory responses through promotion of p65 deacetylation and inhibition of NF-kB activity. PLoS ONE 2012; 7: 1-11
• 23 Grozinger CM, Chao ED, Blackwell HE et al. Identification of a class of small molecule inhibitors of the sirtuins family of NAD⁺-dependent deacetylase by phenotypic screening. J Biol Chem 2001; 276: 38837-38843
• 24 Heltweg B, Gatbonton T, Schuler AD et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res 2006; 66: 4368-4377
• 25 Huber K, Schemies J, Uciechowska U et al. Novel 3-arylideneindolin-2-ones as inhibitors of NAD⁺-dependent histone deacetylases (sirtuins). J Med Chem 2010; 53: 1383-1386
• 26 Lain S, Hollick JJ, Campbell J et al. Discovery, in vivo activity, and mechanism of action of a small molecule p53 activator. Cancer Cell 2008; 13: 454-463
• 27 Lara E, Mai A, Calvanese V et al. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene 2008; 28: 781-791
• 28 Medda F, Russell RJM, Higgins M et al. Novel Cambinol analogs as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activity. J Med Chem 2009; 52: 673-682
• 29 Napper AD, Hixon J, McDonagh T et al. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J Med Chem 2005; 48: 8045-8054
• 30 Nayagam VM, Wang X, Tan YC et al. SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents. J Biomol Screen 2006; 11: 1-8
• 31 Sanders BD, Jackson B, Brent M et al. Identification and characterization of novel sirtuin inhibitor scaffolds. Bioorg Med Chem 2009; 17: 7031-7041
• 32 Suzuki T, Imai K, Imai E et al. Design, synthesis, enzyme inhibition, and tumor cell growth inhibition of 2-anilinobenzamide derivatives as SIRT1 inhibitors. Bioorg Med Chem 2009; 17: 5900-5905
• 33 Suzuki T, Imai K, Nakagawa H et al. 2-Anilinobenzamides as SIRT inhibitors. Chem Med Chem 2006; 1: 1059-1062
• 34 Tavares J, Ouaissi A, Lin PKT et al. Bisnaphthalimidopropyl derivatives as inhibitors of Leishmania SIR2 related protein 1. Chem Med Chem 2010; 5: 140-147
• 35 Trapp J, Meier R, Hongwiset D et al. Structure-activity studies on suramin analogues as inhibitors of NAD⁺-dependent histone deacetylases (sirtuins). Chem Med Chem 2007; 2: 1419-1431
• 36 Uciechowska U, Schemies J, Neugebauer RC et al. Thiobarbiturates as sirtuin inhibitors: virtual screening, free energy calculations, and biological testing. Chem Med Chem 2008; 3: 1965-1976
• 37 Choi G, Lee J, Ji JY et al. Discovery of a potent small molecule SIRT1/2 inhibitor with anticancer effects. Int J Oncol 2013; 43: 1205-1211
• 38 Asaba T, Suzuki T, Ueda R et al. Inhibition of human sirtuins by in situ generation of an acetylated lysine-ADP-ribose conjugate. J Am Chem Soc 2009; 131: 6989-6996
• 39 Toropov AA, Toropova AP, Benfenati E et al. The definition of the molecular structure for potential anti-malaria agents by the Monte Carlo method. Struct Chem 2013; 24: 1369-1381
• 40 OpenBabel version 2.3.2
• 41 Toropova AP, Toropov AA, Benfenati E et al. CORAL: quantitative structure–activity relationship models for estimating toxicity of organic compounds in rats. J Comput Chem 2011; 32: 2727-2733
• 42 Benfenati E, Toropov AA, Toropova AP et al. CORAL Software: QSAR for Anticancer Agents. Chem Biol Drug Des 2011; 77: 471-476
• 43 Cooper JA, Saracci R, Cole P. Describing the validity of carcinogen screening tests. Br J Cancer 1979; 39: 87-89
• 44 Toropov AA, Toropova AP, Rasulev BF et al. CORAL: Binary Classifications (Active/Inactive) for Liver-Related Adverse Effects of Drugs. Curr Drug Saf 2012; 7: 257-261
• 45 Toropov AA, Toropova AP, Benfenati E et al. CORAL: classification model for predictions of anti-sarcoma activity. Curr Top Med Chem 2012; 12: 2741-2744
• 46 Toropov AA, Toropova AP, Lombardo A et al. CORAL: the prediction of biodegradation of organic compounds with optimal SMILES-based descriptors. Cent Eur J Chem 2012; 10: 1042-1048
• 47 Manganelli S, Benfenati E, Manganaro A et al. New Quantitative Structure–Activity Relationship Models Improve Predictability of Ames Mutagenicity for Aromatic Azo Compounds. Tox Sci 2016; 1-11
• 48 Aher RB, Roy K. First report on exploring classification and regression based QSAR modelling of Plasmodium falciparum glycogen synthase kinase (PfGSK-3) inhibitors. SAR QSAR Environ Res 2015; 26: 959-976
• 49 Ojha PK, Roy K. Comparative QSARs for antimalarial endochins: Importance of descriptor-thinning and noise reduction prior to feature selection. Chemometr Intell Lab 2011; 109: 146-161
• 50 Toropov AA, Toropova AP, Lombardo A et al. CORAL: Building up the model for bioconcentration factor and defining it’s applicability domain. Eur J Med Chem 2011; 46: 1400-1403
• 51 Kumar A, Chauhan S. Use of Monte Carlo method for OECD principles guided QSAR modelling of SIRT1 inhibitors. Arch Pharm 2016 (under communication)
• 52 Cao D, Wang M, Qiu X et al. Structural basis for allosteric substrate dependent stimulation of SIRT1 activity by resveratrol. Genes Dev 2015; 29: 1316-1325
• 53 Wu J, Zhang D, Chen L et al. Discovery and mechanism study of SIRT1 activators that promote the deacetylation of fluorophore-labeled substrate. J Med Chem 2013; 56: 761-780
• 54 Mahajan SS, Scian M, Sripathy S et al. Development of pyrazolone and isoxazol-5-one cambinol analogues as sirtuin inhibitors. J Med Chem 2014; 57: 3283-3294